Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Malignant Pleural Mesothelioma Clinical Trials

7 recruiting trials for Malignant Pleural Mesothelioma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
7
Total Trials
7
Recruiting Now
0
Phase 3 Trials
7
Sponsors

Recruiting Trials

RECRUITINGPhase 1 / Phase 2NCT05765084

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line...

In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen...

Sponsor: University Hospital, AntwerpEnrolling: 153 locations
RECRUITINGNCT06910449

Hemithoracic Arc Radiotherapy Post Pleural Decortication

Malignant Pleural Mesothelioma is an aggressive and refractory disease , the most aggressive treatment plan offered to these patients include trimodalitiy approach with...

Sponsor: Cairo UniversityEnrolling: 451 location
RECRUITINGNCT06037941

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 207 locations
RECRUITINGNCT05655078

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).

Sponsor: University College, LondonEnrolling: 14820 locations
RECRUITINGPhase 1NCT03917043

APG-2449 in Patients With Advanced Solid Tumors

APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449...

Sponsor: Ascentage Pharma Group Inc.Enrolling: 1659 locations
RECRUITINGPhase 2NCT06318286

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant...

Sponsor: Hyogo Medical UniversityEnrolling: 251 location
RECRUITINGPhase 2NCT04400539

The IMmunotherapy Pleural 5-ALA PDT

Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with...

Sponsor: University Hospital, LilleEnrolling: 201 location